Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study
Anti-Cancer Drugs, 06/29/2012
Clinical Article
von Gruenigen VE et al. – An oral topotecan dose of 14mg/week for 3 consecutive weeks out of 4 is mostly associated with acceptable toxicities and may be considered for use in future single–agent phase II trials.



